<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04398680</url>
  </required_header>
  <id_info>
    <org_study_id>209627</org_study_id>
    <nct_id>NCT04398680</nct_id>
  </id_info>
  <brief_title>A Study of Belantamab Mafodotin in Multiple Myeloma Participants With Normal and Impaired Hepatic Function</brief_title>
  <acronym>DREAMM 13</acronym>
  <official_title>A Phase I Study to Evaluate the Pharmacokinetics and Safety of Belantamab Mafodotin Monotherapy in Participants With Relapsed or Refractory Multiple Myeloma Who Have Normal and Varying Degrees of Impaired Hepatic Function (DREAMM 13)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the pharmacokinetics (PK), safety, and tolerability of&#xD;
      belantamab mafodotin monotherapy in Relapsed/Refractory Multiple Myeloma (RRMM) participants&#xD;
      with impaired hepatic function and in matched RRMM participants with normal hepatic function.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 20, 2021</start_date>
  <completion_date type="Anticipated">May 6, 2024</completion_date>
  <primary_completion_date type="Anticipated">May 6, 2024</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>Yes</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>This is an open-label study.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Part 1 and Part 2: Maximum observed plasma concentration (Cmax) of GSK2857916</measure>
    <time_frame>Up to 48 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1 and Part 2: Time to Cmax (Tmax) of GSK2857916</measure>
    <time_frame>Up to 48 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1 and Part 2: Concentration at the end of infusion (C-EOI)</measure>
    <time_frame>Up to 48 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1 and Part 2: Predose plasma concentration (Ctrough) of GSK2857916</measure>
    <time_frame>Up to 48 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1 and Part 2: Area under the plasma concentration-time curve (from zero to the end of dosing interval)</measure>
    <time_frame>Up to 48 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1 and Part 2 : AUC over the dosing interval (AUC[0-tau]) of GSK2857916</measure>
    <time_frame>Up to 48 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1 and Part 2: Last time point where the concentration is above the limit of quantification (Tlast) of GSK2857916</measure>
    <time_frame>Up to 48 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1 and Part 2: Cmax of total monoclonal antibody (mAb)</measure>
    <time_frame>Up to 48 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1 and Part 2: Tmax of total mAb</measure>
    <time_frame>Up to 48 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1 and Part 2: C-EOI of total mAB</measure>
    <time_frame>Up to 48 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1 and Part 2: Ctrough of total mAb</measure>
    <time_frame>Up to 48 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1 and Part 2: Area under the plasma concentration-time curve (from zero to the end of dosing interval)of total mAb</measure>
    <time_frame>Up to 48 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1 and Part 2: AUC(0-tau) of total mAb</measure>
    <time_frame>Up to 48 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1 and Part 2: Tlast of total mAb</measure>
    <time_frame>Up to 48 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1 and Part 2: Cmax of Cys Monomethyl Auristatin F (cys-mcMMAF)</measure>
    <time_frame>Up to 48 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1 and Part 2: Tmax of cys-mcMMAF</measure>
    <time_frame>Up to 48 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1 and Part 2: C-EOI of cys-mcMMAF</measure>
    <time_frame>Up to 48 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1 and Part 2: AUC(0-168 hours) of cys-mcMMAF</measure>
    <time_frame>Up to 48 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Part 1 and Part 2: tlast of cys-mcMMAF</measure>
    <time_frame>Up to 48 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part 1 and Part 2: Change from Baseline in Vital Signs- Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) (millimeters of mercury [mmHg])</measure>
    <time_frame>Baseline and up to 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1 and Part 2: Change from Baseline in Vital Sign- Heart rate (beats per minute)</measure>
    <time_frame>Baseline and up to 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1 and Part 2: Number of participants with adverse events (AEs) and serious adverse events (SAEs)</measure>
    <time_frame>Up to 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1 and Part 2: Number of participants with toxicity grading for hematology parameters</measure>
    <time_frame>Up to 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1 and Part 2: Number of participants with toxicity grading for clinical chemistry parameters</measure>
    <time_frame>Up to 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1 and Part 2: Number of participants with toxicity grading for urine parameters</measure>
    <time_frame>Up to 4 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part 1 and Part 2: Number of participants with abnormal physical examination parameters</measure>
    <time_frame>Up to 4 years</time_frame>
    <description>Physical examination parameters will include assessments of the head, eyes, ears, nose, throat, skin, thyroid, lungs, cardiovascular, abdomen (liver and spleen), lymph nodes, and extremities.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">28</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Part 1, Group 1: Participants with normal hepatic function</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with normal hepatic function (Serum bilirubin and Aspartate aminotransferase [AST] less than or equal to [&lt;=] Upper limit of normal [ULN]) will be administered with Belantamab mafodotin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1, Group 2: Participants with moderate hepatic impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with moderate hepatic impairment (Serum bilirubin greater than &gt;1.5 - 3 times ULN and any AST) will be administered with Belantamab mafodotin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2,Group 3: Participants with severe hepatic impairment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with severe hepatic impairment (Serum bilirubin &gt;3 times ULN and any AST) will be administered with Belantamab mafodotin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Belantamab mafodotin</intervention_name>
    <description>Belantamab mafodotin will be administered</description>
    <arm_group_label>Part 1, Group 1: Participants with normal hepatic function</arm_group_label>
    <arm_group_label>Part 1, Group 2: Participants with moderate hepatic impairment</arm_group_label>
    <arm_group_label>Part 2,Group 3: Participants with severe hepatic impairment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participants are capable of giving signed informed consent which includes compliance&#xD;
             with the requirements and restrictions listed in the Informed Consent Form.&#xD;
&#xD;
          -  Male and/or female must be 18 years of age or older, at the time of signing the&#xD;
             informed consent.&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group performance status 0-2.&#xD;
&#xD;
          -  Participants with histologically or cytologically confirmed diagnosis of multiple&#xD;
             myeloma, as defined in International Myeloma Working Group criteria: 1. Has undergone&#xD;
             autologous stem cell transplant (SCT) or is considered transplant-ineligible; 2. Has&#xD;
             failed at least 2 prior lines of anti-myeloma treatments, including an&#xD;
             immunomodulatory drugs (example [e.g.], lenalidomide or pomalidomide) and a proteasome&#xD;
             inhibitor (e.g., bortezomib, ixazomib or carfilzomib).&#xD;
&#xD;
          -  Participants has measurable disease with at least one of the following: Serum&#xD;
             M-protein greater than or equal to (&gt;=)0.5 grams per deciliter (g/dL) &gt;=5 grams per&#xD;
             liter [g/L]); Urine M-protein &gt;=200 milligram per 24 hours (mg/24 hr); and Serum free&#xD;
             light chain assay: Involved free light chain level &gt;=10 milligrams per deciliter&#xD;
             (mg/dL) (&gt;=100 milligrams per liter [mg/L]) and an abnormal serum free light chain&#xD;
             ratio (&lt;0.26 or &gt;1.65).&#xD;
&#xD;
          -  Participants with a history of autologous SCT are eligible for study participation&#xD;
             provided the following eligibility criteria are met: 1. Transplant was &gt;100 days prior&#xD;
             to study enrollment, 2. No active infection(s), and 3. Participant meets the remainder&#xD;
             of the eligibility criteria outlined in this protocol.&#xD;
&#xD;
          -  Participants with adequate organ system functions as defined follows: Absolute&#xD;
             neutrophil count &gt;=1.0 times 10^9/liter (L); Hemoglobin &gt;=8.0 g/dL (or 4.9 millimoles&#xD;
             per liter); Platelets &gt;= 75 times 10^9/L; Serum bilirubin and aspartate&#xD;
             aminotransferase: Group 1 (normal) serum bilirubin and aspartate aminotransferase&#xD;
             &lt;=upper limit of normal (ULN); Group 2 (moderate) serum bilirubin &gt;1.5-3 times ULN and&#xD;
             any aspartate aminotransferase; alanine aminotransferase &lt;=5 ULN; Estimated glomerular&#xD;
             filtration rate &gt;=60 milliliter per minute per 1.73 meter square (mL/min/m^2); Urine&#xD;
             dipstick for protein or Albumin/creatinine ratio (from spot urine) negative/trace (if&#xD;
             &gt;=1+ only eligible if confirmed &lt;=500 mg/g (56 mg/mmol) by albumin/creatinine ratio&#xD;
             (spot urine from first void; and left ventricular ejection fraction by echocardiograms&#xD;
             &gt;=45 percent (%).&#xD;
&#xD;
          -  Main additional inclusion criteria in Group 1 (matched control participants): Matched&#xD;
             to at least one moderate hepatic impaired participant by Baseline albumin levels&#xD;
             (+/-10%) and Baseline weight (+/-20%).&#xD;
&#xD;
          -  Female participants: Contraceptive use by women should be consistent with local&#xD;
             regulations regarding the methods of contraception for those participating in clinical&#xD;
             studies. A female participant is eligible to participate if she is not pregnant or&#xD;
             breastfeeding, and not a woman of childbearing potential (WOCBP) or is a WOCBP and&#xD;
             using a contraceptive method that is highly effective (with a failure rate of &lt;1% per&#xD;
             year).&#xD;
&#xD;
          -  Male participants: Contraceptive use by men should be consistent with local&#xD;
             regulations regarding the methods of contraception for those participating in clinical&#xD;
             studies. Male participants are eligible to participate if they agree to the following&#xD;
             from the time of first dose of study until 6 months after the last dose of study&#xD;
             treatment.&#xD;
&#xD;
          -  Participants with a history of Hepatitis B virus and/or Hepatitis C virus exposure are&#xD;
             eligible under specific conditions.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Active plasma cell leukemia at the time of screening. Symptomatic amyloidosis, active&#xD;
             polyneuropathy, organomegaly, endocrinopathy, myeloma protein and skin changes,&#xD;
             Waldenstroem Macroglobulinemia.&#xD;
&#xD;
          -  Participants had a prior allogeneic SCT.&#xD;
&#xD;
          -  Prior belantamab mafodotin therapy&#xD;
&#xD;
          -  Systemic active infection requiring treatment&#xD;
&#xD;
          -  Any unresolved toxicity &gt;=Grade 2 from previous treatment except for alopecia, or&#xD;
             peripheral neuropathy up to Grade 2.&#xD;
&#xD;
          -  Any serious and/or unstable pre-existing medical, psychiatric disorder or other&#xD;
             conditions (including lab abnormalities except hepatic impairment) that could&#xD;
             interfere with participant's safety, obtaining informed consent or compliance to the&#xD;
             study procedures.&#xD;
&#xD;
          -  Current unstable liver or biliary disease per investigator assessment defined by the&#xD;
             sudden onset of, or clinically relevant changes in: ascites, encephalopathy,&#xD;
             coagulopathy, hypoalbuminemia, esophageal or gastric varices, persistent jaundice, in&#xD;
             the last 14 days prior to the first dose. Participants with cirrhosis are excluded.&#xD;
             Participants with focal lesions due to other causes than underlying multiple myeloma&#xD;
             are excluded.&#xD;
&#xD;
          -  Participants with acute hepatitis B virus infection are excluded. Participants with&#xD;
             chronic hepatitis B infection (active or core antibody positive) are only allowed if&#xD;
             the criteria from Organ System Function are fulfilled and if appropriate antiviral&#xD;
             treatment per local guidance (e.g. tenofovir or entecavir) is started before starting&#xD;
             belantamab mafodotin, continues through to completion of belantamab mafodotin therapy&#xD;
             and is not to be stopped unless advised by local hepatology or virology.&#xD;
&#xD;
          -  Participants with evidence of hepatitis C virus infection, defined as positive&#xD;
             hepatitis C virus - ribonucleic acid test result at screening or within 3 months prior&#xD;
             to first dose of study treatment, are excluded unless successfully treated prior to&#xD;
             enrollment with a curative 8-12 week antiviral treatment course and the hepatitis C&#xD;
             virus - ribonucleic acid negative status has been confirmed after at least 4 weeks&#xD;
             washout of the antiviral treatment.&#xD;
&#xD;
          -  Participants with Gilbert's syndrome.&#xD;
&#xD;
          -  Evidence of cardiovascular risk including any of the following: Evidence of current&#xD;
             clinically significant untreated arrhythmias, including clinically significant&#xD;
             electrocardiogram abnormalities including second degree (Mobitz Type II) or third&#xD;
             degree atrioventricular block; History of myocardial infarction, acute coronary&#xD;
             syndromes (including unstable angina), coronary angioplasty, or stenting or bypass&#xD;
             grafting within 3 months of Screening; Class III or IV heart failure as defined by the&#xD;
             New York Heart Association functional classification system; History of severe&#xD;
             non-ischemic cardiomyopathy; and Uncontrolled hypertension.&#xD;
&#xD;
          -  Known human immunodeficiency virus infection.&#xD;
&#xD;
          -  Current corneal epithelial disease except for mild punctuate keratopathy.&#xD;
&#xD;
          -  Participant is a woman who is pregnant or breastfeeding.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>US GSK Clinical Trials Call Center</last_name>
    <phone>877-379-3718</phone>
    <email>GSKClinicalSupportHD@gsk.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>EU GSK Clinical Trials Call Center</last_name>
    <phone>+44 (0) 20 89904466</phone>
    <email>GSKClinicalSupportHD@gsk.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Krisstina Gowin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90211</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Eli Gabayan</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Plantation</city>
        <state>Florida</state>
        <zip>33322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Jason Eli Tache</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67214</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Shaker R Dakhil</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201-1595</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Mehmet Hakan Kocoglu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>David Vesole</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Monroeville</city>
        <state>Pennsylvania</state>
        <zip>15146</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Kathleen Dorritie</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>The Woodlands</city>
        <state>Texas</state>
        <zip>77380</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Mary Kuntz Crow</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53233</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Michael A Thompson</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Busan</city>
        <zip>49241</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Ho-Jin Shin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Incheon</city>
        <zip>405-760</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Jae Hoon Lee</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Jeonju-si</city>
        <zip>561-172</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Ho-Young Yhim</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Jin Seok Kim</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>May 19, 2020</study_first_submitted>
  <study_first_submitted_qc>May 19, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 21, 2020</study_first_posted>
  <last_update_submitted>October 1, 2021</last_update_submitted>
  <last_update_submitted_qc>October 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>DREAMM 13</keyword>
  <keyword>Belantamab mafodotin monotherapy</keyword>
  <keyword>Hepatic impairment</keyword>
  <keyword>Normal hepatic function</keyword>
  <keyword>Relapsed or refractory multiple myeloma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>IPD for this study will be made available via the Clinical Study Data Request site.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.</ipd_time_frame>
    <ipd_access_criteria>Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.</ipd_access_criteria>
    <ipd_url>http://clinicalstudydatarequest.com</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

